<DOC>
	<DOC>NCT00393393</DOC>
	<brief_summary>That Hylan G-F 20 may act to protect cartilage from the expected degree of degradation over a 12 month period in subjects with moderate to marked osteoarthritis of the knee</brief_summary>
	<brief_title>Effectiveness Study of Hylan G-F 20 to Preserve Cartilage in Osteoarthritis of the Knee</brief_title>
	<detailed_description>Two courses of Hylan G-F 20 ( Synvisc) administered by intra-articular injection at 6 monthly intervals. MRI examinations of the knee for estimation of cartilage volume prior to treatment, before second course and at 12 months in 40 subjects with Grade 2/3 osteoarthritis of knee . A further 40 subjects with similar degree of osteoarthritis of knee who do not receive Hylan G-F therapy will be assessed by MRI in identical manner.</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis, Knee</mesh_term>
	<mesh_term>Hylan</mesh_term>
	<mesh_term>Hyaluronic Acid</mesh_term>
	<criteria>grade 2 or 3 osteoarthritis knee age 18 80 pain score VAS &gt;39 mm on 100mm scale surgery in prior 12 months significant valgus deformity recent trauma use of opioid analgesia unstable medical condition recent corticosteroid injection morbid obesity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2006</verification_date>
	<keyword>osteoarthritis</keyword>
	<keyword>knee</keyword>
	<keyword>hylan</keyword>
</DOC>